Effects of blood pressure and lipid lowering on cognition
Jackie Bosch(Universität Ulm), Carlos García(System Biosciences (United States)), Martin Berli(University of Zurich), William D. Toff(Population Health Research Institute), Basil S. Lewis(Technion – Israel Institute of Technology), Raúl R. Rodrigues-Díez(Universidad Complutense de Madrid), Rafael Díaz(Estudios Clínicos Latinoamérica), A. Ferrari, Balakumar Swaminathan(Roche (Canada)), Marcelo A. Carignano(Qatar Foundation), Eva Lonn(McMaster University), Salim Yusuf(Population Health Research Institute), Alfonsina Candiello, Juan Pablo Cuello(Digestive Care (United States)), María Fernanda Alzogaray, Shun Fu Lee(Population Health Research Institute), Mikul Sharma(Population Health Research Institute), Karen Sliwa(University of Cape Town), C. Damonte, Mátyás Keltai, Marcela Galello, Enrico De Martino(Aalborg University), Nuria Carrillo(National Institutes of Health), Christopher M. Reid(The University of Melbourne), Marina Blanco‐Aparicio, Louis Nuvagah Forti, Arthur Justi Cassettari, Alberto Caccavo, Álvaro Avezum(Sociedade de Nefrologia do Estado de São Paulo), Lawrence A. Leiter(St. Michael's Hospital), Martin O’Donnell(Ollscoil na Gaillimhe – University of Galway), W. Casali, Kamlesh Khunti(University of Leicester), Robert G. Hart(University of British Columbia), Claes Held(Uppsala University), N. Carro, Sandra Cusimano, M. De Landaluc, Gilles R. Dagenais(Institut universitaire de cardiologie et de pneumologie de Québec), Janice M. Pogue(Population Health Research Institute), Antonio Dans(University of the Philippines Manila), B. Bustos, Carlos Alberto Cuneo, M. Bustamante Labarta, Martina Bevacqua, Luis R Cartasegna, Antonio Fernández(Universidad de Las Palmas de Gran Canaria)
Cited by 83
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k